SenesTech, Inc. (SNES) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance, with robust e-commerce and municipal market growth, increased production capacity, and strategic retail expansion plans. The Q&A session highlights ongoing trials, anticipated demand, and international opportunities, although some answers lacked clarity. The absence of a new secondary offering and potential international market contributions further support a positive outlook. Despite some uncertainties, the company's focus on profitability and growth across diverse channels suggests a positive stock price movement in the short term.
Key Financial Performance
Revenue Revenue increased 20% to approximately $2.2 million compared with $1.86 million in 2024. The increase was driven by e-commerce growth and other vertical expansions. Excluding a $200,000 temporary revenue impact from transitioning to directly managing Amazon sales, full-year revenue growth would have been closer to 30%.
E-commerce Revenue E-commerce revenue increased 88%, driven by strong growth on Amazon and the direct-to-consumer website. E-commerce now represents more than half of the total revenue.
Gross Margin Gross margin improved to 62.5% compared with 54.1% in 2024. This improvement reflects an improved product mix and the growing contribution from e-commerce channels.
Net Loss Net loss was $6.4 million compared with $6.2 million in 2024. The 2025 results include approximately $631,000 in one-time legal expenses and $135,000 in non-cash operating lease expense. Excluding these items, the adjusted net loss for the year would have been approximately $5.6 million.
Adjusted EBITDA Loss Adjusted EBITDA loss improved to $5.3 million compared to $5.8 million in 2024, reflecting better financial management and operational improvements.
Cash and Short-term Investments The company ended the year with $8.6 million in cash and short-term investments, providing a solid operating runway.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Evolve Rat and Evolve Mouse: Transitioned to directly managing these products on Amazon, improving product presentation, optimizing marketing, and retaining more revenue.
E-commerce: Fastest-growing segment with 88% revenue growth, driven by Amazon and direct-to-consumer website.
Municipal markets: Increased interest in fertility control approaches in cities like New York and Chicago, with ongoing deployments and trials.
International markets: Expanded footprint with regulatory approvals in New Zealand and Belize, and pending approvals in other regions.
Retail: Engaged with major brick-and-mortar retailers for potential stocking of Evolve products.
Revenue growth: 20% increase in revenue to $2.2 million, with e-commerce now representing over half of total revenue.
Gross margin: Improved to 62.5% from 54.1% in 2024, driven by better product mix and e-commerce contributions.
Legal resolution: Resolved dispute with Liphatech, dismissing all litigation.
Leadership transition: CEO Joel Fruendt retired; interim executive chair appointed, and a formal search for a new CEO is underway.
Resource allocation: Focused on scaling successful areas, maintaining financial discipline, and supporting measurable commercial progress.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The company is undergoing a leadership transition with the retirement of its CEO, Joel Fruendt, and the appointment of an Interim Executive Chair. This could pose risks to strategic continuity and execution during the search for a new CEO.
Revenue Impact from E-commerce Transition: The transition to directly managing Evolve Rat and Evolve Mouse on Amazon caused a temporary revenue impact of approximately $200,000 in Q4 2025, which could affect short-term financial performance.
Legal Dispute Costs: The company incurred approximately $631,000 in one-time legal expenses, including costs associated with resolving a dispute with Liphatech. While the dispute has been resolved, these costs contributed to the net loss for the year.
Net Loss and Financial Performance: The company reported a net loss of $6.4 million for 2025, slightly higher than the $6.2 million loss in 2024. This ongoing financial loss could impact operational sustainability and strategic investments.
Retail Market Challenges: Decision-making in the retail market for stocking Evolve products is a longer process, which could delay revenue growth from this channel.
Pending Regulatory Approvals: The company has potential regulatory approvals pending in certain international markets. Delays or denials in these approvals could hinder international expansion efforts.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
E-commerce Expansion: The company plans to accelerate growth in e-commerce, particularly on Amazon, by directly managing selling activity, optimizing marketing performance, and improving product presentation. E-commerce is expected to continue as the fastest-growing segment, representing more than half of total revenue.
Municipal Market Growth: The company anticipates increased adoption of fertility control approaches in municipal markets, with ongoing deployments in Chicago and potential expansion in New York City following trial conclusions.
International Expansion: The company is expanding its international footprint with regulatory approvals in New Zealand and pending approvals in other regions. Initial stocking orders have been shipped to new distribution partners.
Retail Market Penetration: The company expects to see benefits from groundwork laid in 2025 for retail market penetration, with potential stocking of Evolve products in major brick-and-mortar retailers.
Financial Discipline and Investment: The company plans to maintain financial discipline while investing in high-traction areas such as e-commerce, municipal adoption, and technology validation. Operating expenses will be carefully managed to support measurable commercial progress.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Given that 2025 revenue growth would have been 30%, excluding the impact of transition to directly managing Amazon sales, should we expect similar growth rate in 2026 or could this be higher?
A:Yes, it can be higher. The company aims to accelerate growth in profitable areas.
Q:What are likely to be the contributors to 2026 revenues?
A:Contributors include Amazon and D2C, pest management professionals networks, municipal orders, and international expansion in New Zealand, Belize, and beyond. Growth is expected in e-commerce, municipal trials (e.g., New York), retail (potential explosive growth), and international markets like Australia.
Q:What kind of follow-up should we expect from the 2 field validations in urban areas?
A:The New York trial will conclude in spring, but deployment plans are unknown. Chicago has already begun deployment in some neighborhoods.
Q:Why have all the social media accounts, like Facebook, been quiet since December 2025?
A:The marketing team has been focusing on strengthening core commercial efforts, customer outreach, and sales enablement rather than prioritizing social media. Social media activity will resume with new initiatives this year.
Q:What is the status of the court case of Liphatech versus SenesTech?
A:The case has been settled to the satisfaction of all parties, with immaterial financial and operational impact.
Q:Can you expand upon and clarify the $275,000 one-time legal fees this quarter and whether it's expected to recur?
A:The legal fees are not expected to recur now that the litigation has been resolved. The costs were high but deemed a worthwhile investment due to the positive outcome.
Q:Could you provide more granularity on how much of the legal fees during the last year related to financing?
A:Legal fees related to financing are not classified as operating expenses and are part of the cost of financing, not shown in the income statement.
Q:What is the status of product registration in Australia?
A:The regulatory review is nearing completion, and a response is expected in the spring. A positive outcome is anticipated.
Q:How much revenue do you expect from Belgium during the coming 2 years?
A:The company has no direct input or insight into Belgium as there is no partner in the region.
Q:Can you break out the SG&A, which is up?
A:Details of SG&A and R&D expenses will be available in the 10-K filing. Investors are encouraged to review it and follow up with questions.
Q:What are the new international opportunities?
A:The company cannot comment until agreements are signed. Updates will be shared via press releases.
Q:How likely is it that Evolve Bait gets to brick-and-mortar during the first half of 2026?
A:It is unlikely until at least the end of the second quarter, with more likelihood in the second half of the year.
Q:What municipalities besides New York City are evaluating Evolve?
A:Baltimore has concluded its study and is deploying Evolve. Chicago is assessing fertility control without formal trials. Other smaller municipalities may be conducting informal trials.
Q:How is the agricultural sector working out?
A:The sector is performing well, with successes in almond groves, sugarcane, poultry, and irrigation. Expansion is ongoing.
Q:How soon will you know about the trials in the New York City program?
A:The trial will end in spring (mid-second quarter). Deployment plans are unknown, but discussions with pest management organizations have begun.
Q:How has the e-commerce business been when it comes to Home Depot and Lowe's?
A:These are trial programs for shelf placement decisions. The focus remains on Amazon and the company's website.
Q:Are there any new species you anticipate in 2026 or 2027, such as ground squirrels or gophers?
A:The company is focused on the rodent market (rats and mice) but acknowledges the technology's potential for other mammalian species.
Q:Will evolverodentbirthcontrol.com be available in the future?
A:The site should be up, and the issue will be investigated immediately.
Q:What qualities is the Board looking for in the next CEO?
A:The Board seeks a leader with strong commercial instincts, experience scaling businesses, operational discipline, and the ability to build high-performance teams.
Q:Discussing cash runway implies losses at current revenue levels. Is there any reason why improvement should not be expected?
A:Improvement is expected, but disclosures are conservative as per legal advice.
Q:Inventory grew 25% year-over-year. Is this due to anticipated demand or slower inventory turnover?
A:The growth reflects anticipated demand, ensuring readiness for surge orders from retailers.
Q:Why was Joel not able to be on the call today?
A:The leadership team is aligned and fully engaged in executing the strategy. Joel's absence does not impact progress.
Q:What other target markets will SenesTech focus on this year?
A:The focus remains on existing markets with high potential, such as agriculture, pest management, and municipal sectors.
Q:Have there been any new trials or deployments in major cities on the West Coast?
A:San Francisco has an ongoing trial. UC Irvine Housing project concluded successfully. Other smaller municipalities may have informal trials.
Q:Does management attend industry conferences to showcase Evolve?
A:The sales team attends conferences and meetings with high potential for return, including Pest World and retail shows.
Q:Will the new CEO have incentives built around the company's stock price?
A:Yes, the CEO's compensation will include equity-based incentives aligned with long-term shareholder value.
Q:Do you have any other distributors in California outside of ACE Hardware?
A:Yes, distributors like Agricom and Agri-Turf focus on agriculture, and Veseris and Target Specialty have a strong presence in California.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following: 1. Revenue expectations from Belgium due to lack of partnerships. 2. Details on new international opportunities until agreements are signed. 3. Specificities of SG&A breakdown, directing investors to the 10-K. 4. Deployment plans post-New York trial. 5. Expansion into new species, citing regulatory complexities. 6. Clarification on evolverodentbirthcontrol.com being down. 7. Frequency and duration of follow-up orders from New Zealand. 8. Specificities of new trials or deployments in smaller municipalities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bechtel Chair
Bechtel Interim
Bechtel today
CEO focus
CEO search
CEO today
Chair Chief
Chair SenesTech
Chair position
Dr Bechtel
Executive Chair
Instructions afternoon
Interim Executive
Joel contribution
Officer President
President CEO
SEC filing
SenesTech behalf
SenesTech end
SenesTech year
afternoon SenesTech
alignment CEO
area commerce
behalf Joel
commerce market
continuity transition
contribution position
core area
director experience
discipline resource
discussion risk
expectation risk
experience area
law
today Dr
SNES Transcript
Jefferson Capital, Inc. (JCAP) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call summary indicates strong growth in e-commerce and municipal markets, increased production capacity, and a clear pathway to profitability. The Q&A section suggests stable returns and consistent competition, with management focused on improving efficiency and liquidity. Despite some uncertainty in forward flows and AI impact, the overall sentiment remains positive due to strategic growth plans and operational improvements.
SenesTech, Inc. (SNES) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call summary indicates strong financial performance, with robust e-commerce and municipal market growth, increased production capacity, and strategic retail expansion plans. The Q&A session highlights ongoing trials, anticipated demand, and international opportunities, although some answers lacked clarity. The absence of a new secondary offering and potential international market contributions further support a positive outlook. Despite some uncertainties, the company's focus on profitability and growth across diverse channels suggests a positive stock price movement in the short term.
SenesTech, Inc. (SNES) Q3 2025 Earnings Call Transcript
Positive11-11
The earnings call highlights strong revenue growth, particularly in e-commerce and municipal sales, and a significant increase in gross margins. The company's strategic expansion into new markets and partnerships, along with optimistic guidance for future growth, suggest a positive outlook. Despite legal challenges, the company's financial health remains robust with a strong cash position. The Q&A section reinforces positive sentiment, with discussions on expanding retail presence and international market progress. Overall, the positive financial performance and strategic initiatives outweigh the concerns, leading to a positive stock price prediction.
SenesTech, Inc. (SNES) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary shows strong financial performance with a 36% revenue increase and a significant rise in e-commerce and municipal sales. The Q&A session reinforced positive sentiment with management's plans for growth and no immediate need for further capital raises. Despite some unclear responses, the overall outlook is optimistic with expected growth in key areas, leading to a positive stock price prediction over the next two weeks.
SNES Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
